Chemotherapy Is One Of The Main Ways To Treat Cancer – Part 2 of 3
So, treatments that work on the receptors and drugs that target HER2 don’t work in these cancers. In two new studies, researchers got better results by adding drugs to the prevailing chemo regimen prior to surgery. However, both studies are phase 2 trials, so more research is needed. Both studies are due to be presented Friday at the annual San Antonio Breast Cancer Symposium.
Rugo compared pillar neoadjuvant therapy – paclitaxel (Taxol, others), doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan, others) – to standard psychoanalysis plus the drugs veliparib (investigational) and carboplatin (Paraplatin). Of the 38 women with triple-negative cancer in the study, 52 percent of those getting the extra drugs with the standard approach had no cancer cells identified at surgery, compared with 26 percent of those on the regular therapy.
In a second study, Dr William Sikov, at the Alpert Medical School of Brown University, and colleagues compared the familiar chemotherapy using anthracycline- and taxane-based drugs with three other regimens. These added carboplatin, bevacizumab (Avastin) or both to the standard regimen. The researchers randomly assigned 443 patients with triple-negative teat cancer to one of the four groups.